Literature DB >> 27684298

Upregulation of miR-9 and Let-7a by nanoencapsulated chrysin in gastric cancer cells.

Farideh Mohammadian1,2, Younes Pilehvar-Soltanahmadi1,2, Faraz Zarghami1, Abolfazl Akbarzadeh3, Nosratollah Zarghami1,2.   

Abstract

Chrysin, as a flavone, has showed cancer chemopreventive activity. The present study utilized the PLGA-PEG-chrysin to evaluate the expression of miR-9 and Let-7a in human gastric cells. The structure of nanoparticles and encapsulated chrysin was evaluated using 1H NMR, FT-IR, and SEM. MTT assay was used for the evaluation of cytotoxicity effect of nanoencapsulated chrysin. Expression levels of miR-9 and Let7-a were studied by real-time PCR. The results demonstrated that chrysin-PLGA-PEG nanoparticles are more effective than pure chrysin in upregulation of miR-9 and Let-7a due to enhanced uptake by cells. Therefore, PLGA-PEG could be a superior carrier for this kind of hydrophobic agent.

Entities:  

Keywords:  Let7-a; PLGA–PEG–chrysin; gastric cancer; miR-9; real-time PCR

Mesh:

Substances:

Year:  2016        PMID: 27684298     DOI: 10.1080/21691401.2016.1216854

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  13 in total

1.  Let-7d and miR-185 Impede Epithelial-Mesenchymal Transition by Downregulating Rab25 in Breast Cancer.

Authors:  Arman Shahabi; Behrooz Naghili; Khalil Ansarin; Maryam Montazeri; Mehdi Dadashpour; Nosratollah Zarghami
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

2.  Evaluating the expression level of miR-9-5p and miR-192-5p in gastrointestinal cancer: introducing novel screening biomarkers for patients.

Authors:  Shaian Tavakolian; Hossein Goudarzi; Ebrahim Faghihloo
Journal:  BMC Res Notes       Date:  2020-04-19

Review 3.  Research Progress in microRNA-Based Therapy for Gastric Cancer.

Authors:  Xu Zhao; Gao-Feng Hu; Yan-Fen Shi; Wei Xu
Journal:  Onco Targets Ther       Date:  2019-12-24       Impact factor: 4.147

4.  Combination of metformin and phenformin synergistically inhibits proliferation and hTERT expression in human breast cancer cells.

Authors:  Davoud Jafari-Gharabaghlou; Younes Pilehvar-Soltanahmadi; Mehdi Dadashpour; Ali Mota; Soheila Vafajouy-Jamshidi; Leila Faramarzi; Sara Rasouli; Nosratollah Zarghami
Journal:  Iran J Basic Med Sci       Date:  2018-11       Impact factor: 2.699

5.  Synergistic Growth Inhibitory Effects of Chrysin and Metformin Combination on Breast Cancer Cells through hTERT and Cyclin D1 Suppression

Authors:  Sara Rasouli; Nosratollah Zarghami
Journal:  Asian Pac J Cancer Prev       Date:  2018-04-25

Review 6.  Analysis of the Exposure of Organisms to the Action of Nanomaterials.

Authors:  Anita Staroń; Olga Długosz; Jolanta Pulit-Prociak; Marcin Banach
Journal:  Materials (Basel)       Date:  2020-01-12       Impact factor: 3.623

7.  In-vitro Transcribed mRNA Delivery Using PLGA/PEI Nanoparticles into Human Monocyte-derived Dendritic Cells.

Authors:  Zarin Sharifnia; Mojgan Bandehpour; Hamed Hamishehkar; Nariman Mosaffa; Bahram Kazemi; Nosratollah Zarghami
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

Review 8.  Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives.

Authors:  Ebrahim Rahmani Moghadam; Hui Li Ang; Sholeh Etehad Asnaf; Amirhossein Zabolian; Hossein Saleki; Mohammad Yavari; Hossein Esmaeili; Ali Zarrabi; Milad Ashrafizadeh; Alan Prem Kumar
Journal:  Biomolecules       Date:  2020-09-27

9.  Chrysin Induced Cell Apoptosis Through H19/let-7a/COPB2 Axis in Gastric Cancer Cells and Inhibited Tumor Growth.

Authors:  Lin Chen; Qirong Li; Ziping Jiang; Chengshun Li; Haobo Hu; Tiedong Wang; Yan Gao; Dongxu Wang
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244

Review 10.  The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection.

Authors:  Jiulue Hu; Jelena Stojanović; Saman Yasamineh; Pooneh Yasamineh; Sathish Kumar Karuppannan; Mohammed Junaid Hussain Dowlath; Hamed Serati-Nouri
Journal:  Arch Virol       Date:  2021-07-19       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.